OKYO Pharma Limited (NASDAQ:OKYO - Get Free Report)'s stock price traded up 0.5% on Monday . The company traded as high as $1.95 and last traded at $1.85. 2,459,157 shares traded hands during trading, an increase of 1,766% from the average session volume of 131,758 shares. The stock had previously closed at $1.84.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of OKYO Pharma in a research report on Monday, May 5th.
View Our Latest Stock Report on OKYO
OKYO Pharma Stock Performance
The business's 50-day moving average is $1.41 and its two-hundred day moving average is $1.23.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in OKYO Pharma stock. Dauntless Investment Group LLC bought a new position in OKYO Pharma Limited (NASDAQ:OKYO - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,988,780 shares of the company's stock, valued at approximately $2,526,000. OKYO Pharma comprises about 3.0% of Dauntless Investment Group LLC's investment portfolio, making the stock its 2nd largest position. Dauntless Investment Group LLC owned approximately 5.88% of OKYO Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 2.97% of the company's stock.
OKYO Pharma Company Profile
(
Get Free Report)
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.
Recommended Stories
Before you consider OKYO Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OKYO Pharma wasn't on the list.
While OKYO Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
